Table 1.
Basal characteristics and medication prescribed in the study participants.
| PLC (n = 34) | MO (n = 31) | p # | |
|---|---|---|---|
| BMI < 25, n (%) | 6 (18) | 4 (13) | 0.561 |
| 25–29.9, n (%) | 17 (50) | 13 (42) | |
| ≥30, n (%) | 11 (32) | 14 (45) | |
| Fat_Status | 0.683 | ||
| Normal, n (%) | 8 (23.5) | 6 (19.4) | |
| Above normal, n (%) | 26 (76.5) | 25 (80.6) | |
| Body fat excess (%) a | 5.1 ± 6.2 | 5.7 ± 4.4 | 0.327 |
| Lipid lowering agents, n (%) | 8 (23.5) | 10 (32.3) | 0.432 |
| Antihypertensive agents, n (%) | 9 (26.5) | 7 (22.6) | 0.716 |
| MEDAS score | 9.5 ± 2.5 | 10.2 ± 1.8 | 0.208 |
| Physical activity (kcal/week) | 4591 ± 2831 | 3890 ± 2176 | 0.279 |
# Chi2 or Student’s t test (independent samples). a Body fat excess is calculated as body fat percentage minus the high threshold of the normal body fat percentage range for men and women according to Gallagher et al. (2000) [40] for the corresponding age group (40–59 year or 60–70 year). PLC: placebo; MO: Moringa oleifera Lam.